Cardinal Capital Management Takes Position in Pfizer Inc. $PFE

Key Points

• Cardinal Capital Management acquired a new Q4 stake in Pfizer of 120,229 shares (≈$2.99M), amid broader institutional buying that leaves institutions owning about 68.36% of the company.
• Pfizer reached settlement agreements that effectively extend U.S. exclusivity for its heart drug Vyndamax until about 2031, delaying generic competition and protecting medium‑term revenue.
• Pfizer announced a quarterly dividend of $0.43 (annualized $1.72), representing a 6.5% yield

Cardinal Capital Management acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 120,229 shares of the biopharmaceutical company's stock, valued at approximately $2,994,000.

Other hedge funds also recently made changes to their positions in the company. Brighton Jones LLC increased its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank increased its position in shares of Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock worth $1,408,000 after purchasing an additional 6,415 shares in the last quarter. Sei Investments Co. increased its position in shares of Pfizer by 31.5% during the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company's stock worth $63,889,000 after purchasing an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC increased its position in shares of Pfizer by 45.3% during the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company's stock worth $2,480,000 after purchasing an additional 31,896 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reached settlement agreements with three generic makers that effectively extend exclusivity on its heart drug, keeping generic rivals out of the U.S. market until about 2031 — a meaningful revenue-protection outcome for the product. Pfizer secures deals to keep heart drug free of generic rivals until 2031
• Positive Sentiment: Multiple outlets report the settlements specifically extend the effective U.S. patent life for Vyndamax (the branded heart drug), which should delay revenue erosion from generics and supports medium-term cash flow. Pfizer Stock Is Declining Today: What's Happening?
• Neutral Sentiment: Analyst and media pieces revisit Pfizer's dividend and income appeal (high yield), which supports longer‑term buy-and-hold interest even amid short-term volatility. Is Pfizer (PFE) One of the Best Fortune 500 Dividend Stocks to Invest in Right Now?
• Neutral Sentiment: Broader comparisons and strategy pieces (Novo Nordisk vs. Pfizer; buy/sell/hold guidance) highlight pipeline choices and longer-term growth questions — useful context but not immediate price drivers. Should You Buy, Sell, or Hold Pfizer at $27?
• Negative Sentiment: Zacks warns Q1 earnings are expected to decline and that Pfizer may lack the setup for an earnings beat this quarter — a near-term catalyst likely contributing to selling pressure. Earnings Preview: Pfizer (PFE) Q1 Earnings Expected to Decline
• Negative Sentiment: Market wrap and news roundups note Pfizer underperformed the broader market today — analysts attribute that to profit-taking, elevated volume of selling, and investor concern about near-term sales/earnings momentum despite the patent settlements. Why Pfizer (PFE) Dipped More Than Broader Market Today
• Negative Sentiment: Consumer-facing coverage flags the stock decline and summarizes investor uncertainty, reinforcing short-term negative sentiment and contributing to momentum-based selling. Pfizer stock is declining today: What's happening?

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on PFE shares. UBS Group increased their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Monday, April 13th. TD Cowen reiterated a "hold" rating on shares of Pfizer in a research report on Tuesday, December 30th. Zacks Research upgraded shares of Pfizer from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 24th. Barclays started coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an "underweight" rating and a $25.00 target price for the company. Finally, BMO Capital Markets reiterated an "outperform" rating and set a $30.00 target price on shares of Pfizer in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $28.48.

Pfizer Stock Down 1.3%

Shares of NYSE PFE opened at $26.45 on Wednesday. The firm has a market capitalization of $150.37 billion, a PE ratio of 19.44 and a beta of 0.43. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 1 year low of $21.97 and a 1 year high of $28.75. The firm's 50-day moving average is $27.20 and its 200-day moving average is $26.09.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same quarter last year, the firm earned $0.63 EPS. Pfizer's quarterly revenue was down 1.2% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.5%. Pfizer's dividend payout ratio (DPR) is presently 126.47%.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.